Drug Shortage Report for TEVETEN PLUS

Last updated on 2020-09-29 History
Report ID 124719
Drug Identification Number 02253631
Brand name TEVETEN PLUS
Common or Proper name EPROSARTAN HYDROCHLOROTHIAZIDE
Company Name BGP PHARMA ULC
Market Status CANCELLED POST MARKET
Active Ingredient(s) EPROSARTAN HYDROCHLOROTHIAZIDE
Strength(s) 600MG 12.5MG
Dosage form(s) TABLET
Route of administration ORAL ORAL
Packaging size 2x14
ATC code C09DA
ATC description ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
Reason for shortage Requirements related to complying with good manufacturing practices.
Anticipated start date 2020-09-30
Actual start date
Estimated end date 2020-10-28
Actual end date 2020-09-28
Shortage status Avoided shortage
Updated date 2020-09-29
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 85 ADVANCE ROAD
ETOBICOKE, ONTARIO
CANADA M8Z 2S6
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v4 2020-09-29 French Compare
v3 2020-09-29 English Compare
v2 2020-09-22 French Compare
v1 2020-09-22 English Compare

Showing 1 to 4 of 4